The biotech firm argenx has been making significant strides recently and is attracting a lot of investor attention. The FDA is considering regulatory actions on argenx’s Vyvgart Hytrulo due to reports of the 'severe worsening' of diseases. Argxenx has also planned to move ARGX-119 into a registrational study and intends to report its half year 2025 financial results on July 31. The massive exclusive macrocyclic peptide discovery deal with Unnatural Products worth $1.5 billion garnered much interest as well. BofA remains bullish on Argenx with a Buy rating and $804 PT. Several studies carried out by Argenx, especially the promising Phase 2 Study on Efgartigimod PH20 SC for systemic sclerosis, potentially a game-changer for treating myopathy, are drawing positive attention. Meantime, the EC has approved argenx’s efgartigimod alfa for CIDP treatment. However, caution alerts from Pomerantz Law Firm investigating claims on behalf of Argenx's investors, and the drop in its stocks despite beating sales expectations can't be overlooked.
argenx News Analytics from Mon, 13 Jan 2025 08:00:00 GMT to Fri, 25 Jul 2025 20:26:40 GMT - Rating 6 - Innovation 8 - Information 5 - Rumor -3
